Bavarian Nordic rises 3% after guidance hike

Bavarian Nordic A/S

12/05/2026 08:20

** Shares in Bavarian Nordic BAVA.CO rise 3% after the Danish vaccine maker raised its 2026 forecast, following the U.S. government's award of an additional option for its smallpox vaccine

** It raised 2026 revenue guidance to 5.5 billion to 5.7 billion Danish crowns ($865.2-$896.7 million), from the earlier outlook of 5 billion crowns to 5.2 billion crowns

** The guidance hike follows the U.S. government's exercise of options totalling $97 million under an existing contract for the supply of freeze-dried Jynneos smallpox vaccine

** Jefferies says supplemental payments within the option may also deliver minor secured revenues for 2027 and beyond

** The brokerage adds, however, that M&A remains key for a sustained re-rating

** The stock is among best performers on pan-European STOXX 600 .STOXX index, which is down 1%

($1 = 6.3566 Danish crowns)

(Reporting by Vera Dvorakova)

((vera.dvorakova@thomsonreuters.com))